chikungunya
viru
chikv
transmit
aed
mosquito
import
grow
human
health
concern
mani
countri
caus
signific
outbreak
acut
febril
ill
longterm
arthropathi
origin
trace
africa
enzoot
spillov
belong
semliki
forest
complex
alphaviru
togavirida
first
isol
human
patient
tanzania
current
exist
four
lineag
two
african
enzoot
lineag
west
african
wa
east
central
south
africa
ecsa
lineag
addit
two
lineag
origin
ecsa
lineag
call
asian
recent
emerg
indian
ocean
lineag
chikv
compos
posit
singlestrand
genom
rna
kilobas
encod
four
nonstructur
ns
five
structur
protein
nonstructur
protein
requir
viru
replic
subgenom
rna
encod
structur
protein
capsid
c
thu
polyprotein
produc
process
capsid
autoproteinas
signalas
chikv
surfac
mainli
compos
heterodim
glycoprotein
mediat
fusion
glycoprotein
interact
host
receptor
sinc
discoveri
viru
spread
asia
oceaniapacif
europ
mostli
recent
america
million
report
case
sinc
detect
late
whilst
major
outbreak
continu
record
asian
african
contin
although
chikungunya
vaccin
develop
sever
decad
licens
option
yet
avail
chikv
still
caus
substanti
morbid
overwhelm
public
health
system
contribut
poverti
meantim
current
control
strategi
reli
reduc
human
exposur
potenti
infect
mosquito
vector
sever
institut
engag
develop
safe
costeffect
chikv
vaccin
vaccin
base
liveattenu
inactiv
chikv
chimer
chikv
dna
subunit
viruslik
particl
vlp
viralvector
platform
mainli
design
induc
humor
respons
structur
viral
protein
well
due
strong
correl
protect
neutralis
antibodi
structur
chikv
protein
asymptomat
case
addit
passiv
transfer
sera
convalesc
human
mice
prevent
infect
whilst
neutralis
antibodi
abl
protect
immunocompromis
mice
human
earli
neutralis
respons
associ
reduc
clinic
symptom
asymptomat
case
associ
high
neutralis
antibodi
titr
describ
design
develop
chikv
vaccin
base
clinic
relev
adenovir
vector
modifi
vaccinia
ankara
mva
platform
viral
vector
express
schikv
protein
abl
form
chikungunya
viral
particl
thu
mimick
real
exposur
chikv
whilst
silico
design
mosaic
protein
aim
repres
four
chikv
lineag
mice
vaccin
candid
express
schikv
antigen
abl
induc
strong
humor
cellular
respons
upon
singl
nonadjuv
immunis
approach
importantli
present
evid
vitro
neutralis
activ
sera
vaccin
mice
final
whilst
durabl
humor
respons
achiev
upon
singl
immunis
mva
vaccin
express
schikv
produc
use
altern
heterolog
booster
regim
order
increas
neutralis
antibodi
titr
taken
togeth
viral
vector
vaccin
chikv
base
platform
good
candid
preclin
clinic
studi
full
length
structur
polyprotein
sequenc
chikv
lineag
collect
ncbi
protein
databas
align
use
clustal
omega
neighbourjoin
tree
creat
jukecantor
bootstrap
conserv
within
clade
intraclad
subsequ
clade
calcul
use
inhous
develop
softwar
base
slide
window
approach
sequenc
weight
method
enabl
equal
represent
lineag
variant
manuscript
prepar
structur
cassett
chikv
sequenc
deriv
variou
chikv
lineag
codon
optimis
improv
initi
translat
kozak
consensu
sequenc
includ
end
transgen
final
transgen
design
includ
requir
enzymat
restrict
site
allow
infram
clone
transgen
cmv
promot
polya
sequenc
region
contain
shuttl
express
vector
pmono
synthet
gene
cassett
produc
fisher
scientif
regensburg
germani
name
schikv
schikv
plasmid
use
dna
templat
gener
cassett
capsid
pcrclone
variant
name
schikv
forward
primer
atggaggaatggtccctggctatc
revers
primer
tcatcagtgccggctgaag
plasmid
contain
schikv
cassett
c
schikv
digest
kpni
noti
restrict
enzym
neb
ipswich
usa
allow
infram
ligat
cmv
promot
poli
region
contain
shuttl
plasmid
pmono
recombin
dna
plasmid
expand
purifi
e
coli
use
midiprep
kit
qiagen
hilden
germani
result
plasmid
verifi
restrict
analysi
flank
sequenc
gener
vaccin
shuttl
plasmid
contain
attl
region
sequenc
recombin
attr
region
contain
destin
vector
use
vitro
gateway
reaction
lr
clonas
ii
system
invitrogentm
carlsbad
ca
usa
success
recombin
schikv
schikv
plasmid
verifi
dna
sequenc
use
flank
primer
forward
promot
primer
poli
revers
primer
standard
cell
biolog
virolog
techniqu
perform
gener
nonrepl
adenovir
vector
gener
mva
base
vaccin
schikv
schikv
cassett
digest
kpni
xhoi
allow
infram
ligat
promot
tkr
locu
contain
entri
plasmid
mva
ligat
dna
plasmid
expand
e
coli
midiprep
qiagen
use
plasmid
purif
result
plasmid
verifi
restrict
analysi
flank
sequenc
cotransfect
produc
mva
schikv
mva
schikv
use
methodolog
previous
describ
control
mva
vector
compris
nonstructur
ns
region
chikv
name
ns
mva
ns
respect
femal
inbr
balbc
week
use
assess
immunogen
n
mice
per
group
mice
purchas
envigo
rm
inc
bicest
gb
experiment
design
took
account
reduct
replac
reduct
refin
randomis
use
work
chimpanze
adenoviralvector
vaccin
mice
vaccin
intramuscularli
singl
dose
infecti
unit
iu
boost
mva
vaccin
administ
dose
plaqueform
unit
pfu
per
mous
vaccin
dilut
endotoxinfre
pb
vero
cell
grown
follow
atcc
condit
cell
grown
dmem
media
supplement
fb
lglutamin
nonessenti
amino
acid
babi
hamster
cell
maintain
minimum
essenti
medium
gmem
supplement
fetal
bovin
serum
fb
lglutamin
tryptos
phosphat
broth
mm
hepe
ph
uml
penicillin
mgml
streptomycin
cell
number
viabil
calcul
trypan
blue
stain
use
countess
autom
cell
counter
life
technolog
carlsbad
ca
usa
cell
line
describ
ncbi
biosampl
databas
express
screen
carri
vero
cell
transduct
schikv
use
moi
three
day
transduct
cell
supernat
harvest
supernat
concentr
kda
spin
column
millipor
uk
ltd
concentr
fraction
nonconcentr
fraction
input
flow
fraction
also
recov
cell
supernat
sampl
boil
five
minut
laemli
buffer
equal
amount
total
cell
extract
cell
supernat
resolv
sdspage
transfer
pvdf
membran
blot
block
pbstween
milk
incub
antichikv
antibodi
az
aalto
bioreag
dublin
ireland
dilut
antichikv
envelop
seroposit
mice
sera
follow
incub
hrpconjug
secondari
antibodi
chemiluminesc
perkinelm
life
scienc
boston
usa
visualis
use
chemidoc
sr
devic
biorad
watford
h
uk
formvarcarbon
mesh
cu
grid
glowdischarg
air
load
sampl
schikv
vaccin
stock
purifi
vlp
chikv
sucros
gradient
excess
liquid
remov
grid
wash
time
milliq
water
final
grid
stain
uranyl
acet
excess
uranyl
acet
care
remov
use
filter
paper
grid
air
dri
analys
transmiss
electron
microscop
fei
eindhoven
netherland
elispot
carri
use
peripher
blood
mononuclear
cell
pbmc
briefli
maip
elispot
plate
millipor
uk
ltd
coat
antimous
antibodi
mab
mabtech
block
complet
dmem
media
fc
isol
pbmc
use
ack
buffer
solut
plate
alongsid
specif
chikv
structur
peptid
overlap
aa
splenocyt
mice
per
well
h
incub
cell
discard
plate
wash
pb
follow
biotinyl
antimous
mab
mab
mabtech
pb
ad
well
incub
h
wash
plate
incub
streptavidinalp
mabtech
dilut
pb
h
anoth
wash
step
develop
solut
biorad
watford
h
uk
use
spot
visibl
reaction
stop
rins
plate
water
spot
acquir
use
elispot
reader
spot
form
cell
sfc
pbmc
produc
calcul
express
purif
chikv
protein
codonoptimis
gene
aa
clone
phlsec
vector
flank
chicken
hybrid
promot
signal
secret
sequenc
tag
order
improv
secret
protein
ctermin
region
aa
delet
phlsec
chikv
plasmid
transfect
cell
use
polyethyleneimin
pei
roller
bottl
surfac
area
standard
cell
cultur
condit
five
day
transfect
cell
discard
media
filter
dispos
filter
secret
protein
purifi
supernat
ni
sepharos
affin
chromatographi
histraptm
ge
healthcar
use
start
chromatographi
system
elut
imidazol
final
elut
protein
dialys
use
slidealyzertm
cassett
thermo
fisher
scientif
rockford
il
usa
pb
antibodi
bind
chikv
measur
igg
enzym
link
immunosorb
assay
elisa
briefli
mice
sera
dilut
nunc
maxisorp
immuno
elisa
plate
coat
dilut
pb
final
concentr
incub
room
temperatur
overnight
plate
wash
time
tween
pbst
block
piercetm
proteinfre
pb
block
buffer
thermo
fisher
scientif
waltham
usa
h
rt
mice
serum
ad
serial
dilut
pbst
per
well
final
volum
incub
h
rt
follow
wash
time
pbst
bound
antibodi
detect
follow
h
incub
alkalin
phosphataseconjug
antibodi
specif
whole
mous
igg
sigma
aldrich
st
loui
mo
usa
follow
addit
wash
pbst
develop
achiev
use
dilut
diethanolamin
buffer
absorb
valu
measur
analys
use
clariostar
instrument
bmg
labtech
aylesburi
gb
serum
antibodi
endpoint
titr
defin
absorb
valu
three
standard
deviat
greater
averag
control
titr
neutralis
antibodi
determin
describ
previous
use
chikv
replicon
particl
vrp
express
gaussia
luciferas
gluc
briefli
cell
seed
plate
cell
per
well
next
day
vrp
moi
preincub
serial
dilut
serum
sampl
h
mixtur
ad
plate
incub
h
inoculum
remov
cell
wash
pb
medium
ad
readout
secret
gaussia
perform
h
post
infect
use
renilla
luciferas
assay
system
promega
southhampton
uk
neutralis
potenc
determin
percentag
measur
gluc
activ
compar
gluc
readout
vrp
applic
without
serum
result
present
neutralis
titr
anim
procedur
use
accord
term
uk
home
offic
anim
act
project
licens
procedur
approv
univers
oxford
anim
care
ethic
review
committe
ppl
author
declar
data
support
find
studi
shown
articl
order
gener
structur
gene
cassett
c
chikv
protein
sequenc
mosaic
construct
use
fulllength
structur
polyprotein
sequenc
collect
ncbi
protein
databas
neighbourjoin
tree
creat
identifi
three
distinct
clade
b
c
figur
subsequ
conserv
assess
within
clade
intraclad
figur
use
slide
window
approach
conserv
valu
assign
fulli
conserv
anyth
lower
first
quartil
class
conserv
lastli
number
window
conserv
across
clade
degre
conserv
identifi
use
creat
normalis
mosaic
consensu
figur
illustr
level
share
conserv
clade
fulli
conserv
result
sequenc
mosaic
schikv
synthesis
figur
construct
chimpanze
adenovir
vector
vaccin
express
full
structur
cassett
schikv
capsiddelet
structur
cassett
schikv
nonstructur
sequenc
chikv
ns
latter
use
control
vaccin
figur
addit
modifi
vaccinia
ankara
mva
viralvector
use
construct
mva
schikv
mva
schikv
control
mva
ns
figur
clone
product
vaccin
encod
genom
schikv
cassett
verifi
format
adenovir
particl
transmiss
electron
microscopi
figur
describ
cellular
express
full
structur
chikv
cassett
capabl
selfassembl
vlp
chikv
well
alphavirus
collect
supernat
cell
express
schikv
antigen
supernat
subject
sucros
gradient
show
characterist
sediment
band
repres
vlp
accumul
figur
left
electron
microscopi
prepar
reveal
particl
approxim
nm
size
figur
right
resembl
wildtyp
chikv
particl
altern
transduc
vero
cell
schikv
schikv
verifi
express
cell
supernat
specif
detect
achiev
western
blot
use
antichikv
mice
serum
monoclon
antibodi
figur
respect
cell
transduc
schikv
detect
band
approxim
kda
supernat
figur
lane
band
approxim
kda
concentr
supernat
figur
lane
cellular
extract
detect
specif
band
kda
figur
lane
cell
transduc
schikv
also
detect
band
approxim
kda
supernat
figur
lane
band
kda
kda
found
concentr
supernat
cell
extract
therefor
suggest
kda
kda
band
may
repres
capsid
protein
previous
demonstr
present
schikv
cell
posit
control
use
commerci
avail
chikv
protein
figur
lane
therefor
suggest
kda
band
detect
blot
protein
addit
western
blot
perform
use
monoclon
antibodi
chikv
figur
detect
specif
band
posit
control
protein
lane
well
kda
band
supernat
fraction
schikv
schikv
cell
signal
cell
extract
detect
figur
lane
probabl
due
conform
epitop
mask
taken
togeth
result
suggest
adenoviralvector
abl
express
schikv
antigen
abl
induc
format
chikungunya
virallik
particl
thu
aim
mimic
real
antigen
exposur
chikv
particl
assess
specif
immunogen
viralvector
vaccin
immunis
group
balbc
anim
n
singl
nonadjuv
vaccin
dose
schikv
schikv
control
ns
respect
two
week
immunis
cell
respons
quantifi
ex
vivo
elispot
use
specif
pool
overlap
peptid
span
full
chikv
structur
cassett
well
pool
overlap
peptid
relat
control
ns
vaccin
figur
balbc
mice
receiv
vaccin
encod
schikv
antigen
show
high
cell
frequenc
stimul
schikv
peptid
pool
schikv
mean
spotform
cell
sfc
peripher
blood
mononuclear
cell
pbmc
schikv
mean
pbmc
statist
differ
group
use
oneway
anova
analysi
figur
control
group
ns
show
low
specif
cell
respons
ns
peptid
pool
respons
specif
schikv
peptid
pool
addit
analys
respons
toward
specif
peptid
subpool
c
ns
figur
schikv
peptid
deconvolut
elispot
allow
identif
immunodomin
region
locat
region
induc
upon
schikv
schikv
vaccin
pbmc
respect
expect
detect
specif
cellular
respons
toward
capsid
anim
vaccin
schikv
pbmc
comparison
anim
vaccin
schikv
low
background
respons
record
figur
modest
respons
detect
pbmc
peptid
pool
taken
togeth
conclud
singl
inject
schikv
schikv
immunogen
abl
induc
specif
cell
respons
balbc
mice
assess
humor
respons
plate
coat
protein
perform
elisa
assay
identifi
immunogen
properti
schikv
schikv
upon
singl
unadjuv
vaccin
strategi
figur
two
week
schikv
schikv
vaccin
specif
igg
antibodi
bind
chikv
protein
detect
sera
vaccin
anim
figur
left
six
week
prime
figur
right
anim
increas
level
bind
protein
particular
interest
month
singl
immunis
sera
vaccin
anim
show
specif
igg
antibodi
bind
chikv
similar
six
week
prime
group
figur
bottom
ns
use
control
gener
antibodi
respons
toward
schikv
antigen
log
reciproc
antibodi
titr
analysi
figur
show
level
antibodi
increas
time
schikv
schikv
primevaccin
anim
remark
maintain
month
upon
singl
vaccin
strategi
interestingli
result
indic
delet
capsid
schikv
vaccin
group
impair
abil
elicit
chikv
antibodi
titr
final
modifi
vaccinia
ankara
mva
viralvector
technolog
shown
potent
booster
immun
respons
therefor
construct
mva
schikv
mva
schikv
test
boost
immunogen
potenti
primeboost
heterolog
strategi
mice
immunis
either
schikv
schikv
boost
mva
schikv
mva
schikv
six
week
prime
respect
sera
collect
two
week
boost
primeboost
vaccin
mice
show
high
endpoint
titter
anti
antibodi
figur
primeboost
section
mva
ns
use
control
boost
anim
vaccin
ns
vaccin
taken
togeth
conclud
singl
vaccin
adjuv
strategi
abl
induc
earli
specif
longlast
b
respons
balbc
mice
toward
protein
test
balbc
mice
sera
obtain
earli
prime
timepoint
primeboost
vaccin
assess
chikv
antibodi
neutralis
activ
vitro
method
use
base
viru
replicon
particlebas
vrp
chikungunya
viru
neutralis
assay
determin
valu
control
ns
sera
includ
alongsid
assay
two
week
postvaccin
sera
schikv
schikv
group
show
high
neutralis
activ
vrp
chikv
titr
respect
figur
primeboost
regim
figur
schikvmva
schikv
show
increas
titter
comparison
prime
vaccin
regim
schikv
similar
increas
titr
found
sera
mice
vaccin
primeboost
schikv
schikv
increas
compar
titr
singl
schikv
vaccin
anim
figur
result
indic
capsid
delet
chikv
structur
gene
decreas
antibodi
titr
observ
upon
singl
vaccin
convers
primeboost
regim
use
delet
capsid
benefici
increas
chikv
antibodi
titr
taken
togeth
result
confirm
viralvector
vaccin
elicit
function
neutralis
antibodi
chikvinfect
particl
test
vitro
model
work
construct
chikv
vaccin
base
viralvector
platform
mva
vector
immunogen
design
base
mosaic
consensu
sequenc
asian
east
central
south
african
west
african
region
although
individu
strain
antigen
relat
chikv
vaccin
previous
report
develop
use
heterolog
strain
mosaicbas
approach
ensur
high
coverag
aim
rais
neutralis
antibodi
variant
circul
worldwid
develop
two
differ
vaccin
immunogen
candid
vaccin
encod
full
structur
chikv
polyprotein
schikv
vaccin
capsid
antigen
delet
schikv
one
function
capsid
autocleav
polyprotein
proteolyt
process
expos
signal
leader
contain
aminotermin
region
promot
entri
polyprotein
endoplasm
reticulum
sever
advantag
compar
two
differ
antigen
cassett
genet
vaccin
dna
vaccin
rna
vaccin
viralvector
vaccin
often
limit
number
nucleotid
insert
antigen
cassett
explor
minimum
sequenc
length
abl
induc
immunogen
efficaci
either
vitro
neutralis
steril
protect
viral
challeng
inform
vaccin
develop
new
gener
vaccin
candid
chikv
addit
optimis
minimum
number
genet
antigen
could
allow
inclus
antigen
creat
combin
vaccin
either
homolog
heterolog
induc
immun
respons
differ
pathogen
singl
genet
vaccin
approach
base
assumpt
effort
underway
creat
vaccin
express
shorter
version
chikv
polyprotein
protein
chikv
alphavirus
protein
involv
receptor
recognit
protein
involv
membran
fusion
therefor
explor
singleprotein
chikv
vaccin
viralvector
platform
seem
feasibl
promis
sinc
antibodi
high
convalesc
chikvimmun
popul
howev
ensur
proper
antigen
fold
develop
ident
similar
antigen
structur
virion
chikv
paramount
demonstr
transmiss
electron
microscopi
adenovir
vaccin
schikv
capabl
express
chikungunyavlp
promot
correct
conform
antigen
present
upon
vaccin
therefor
mimick
real
exposur
wildtyp
chikv
interest
explor
compar
neutralis
efficaci
encod
chikungunyavlp
protein
viralvector
vaccin
work
test
immunogen
viralvector
vaccin
assess
cellular
humor
respons
balbc
mice
data
show
cell
immunogen
elicit
schikv
schikv
direct
primarili
peptid
region
locat
protein
product
interest
explor
develop
tcell
base
vaccin
chikv
role
cell
immun
alphaviru
infect
especi
chikv
well
understood
importantli
antigen
design
modul
intracellular
express
play
major
role
induc
cell
respons
direct
antigen
clear
exampl
comparison
chikv
chikv
elispot
cell
respons
direct
capsid
detect
chikv
group
ablat
chikv
group
interest
explor
protect
immunolog
relev
cell
respons
direct
capsid
preclin
model
although
identifi
immunodomin
region
balbc
observ
may
differ
inbr
outbr
mous
strain
case
vaccin
compris
antigen
exampl
chikvspecif
cell
direct
mainli
protein
mice
cell
induc
chikv
infect
mice
essenti
control
viremia
cell
involv
chikv
patholog
furthermor
cell
adopt
transfer
confer
protect
chikv
challeng
final
cell
respons
human
chikv
infect
also
poorli
understood
cell
respons
found
chronic
convalesc
chikv
patient
specif
respons
detect
capsid
ns
protein
studi
use
chikv
challeng
model
would
inform
dissect
role
cellular
respons
protect
efficaci
use
vaccin
platform
term
humor
respons
assess
bind
antibodi
vaccin
mice
elisa
coat
protein
protein
shown
primari
target
neutralis
antibodi
sinc
function
recognit
attach
cellular
receptor
demonstr
vaccin
abl
mount
antibodi
respons
level
antibodi
respons
singl
immunis
schikv
schikv
maintain
month
highlight
suitabl
vaccin
approach
promot
longlast
immun
respons
chikv
nonetheless
test
boost
strategi
use
mva
chikungunya
vaccin
increas
antibodi
titr
although
use
elisa
assay
detect
antibodi
possibl
detect
antibodi
monomer
howev
vaccin
platform
assembl
vlp
chikv
conform
epitop
might
physiolog
relev
confer
protect
efficaci
preclin
model
final
rule
possibl
induc
respons
structur
compon
schikv
schikv
prompt
respons
b
tcell
compart
vitro
neutralis
assay
excel
standard
test
capac
chikv
seroposit
serum
neutralis
chikv
utilis
wide
use
neutralis
assay
use
noninfecti
chikv
particl
fulli
capabl
pack
chikv
replicon
rna
carri
gaussia
luciferas
gluc
gene
locat
subgenom
rna
region
therefor
infect
cell
secret
gluc
detect
surrog
detect
chikv
infect
studi
test
rather
earli
timepoint
schikv
schikv
prime
vaccin
hope
demonstr
efficaci
neutralis
two
week
postvaccin
vaccin
aim
guarante
protect
shortest
window
time
vaccin
pathogen
exposur
convers
test
neutralis
capac
upon
booster
vaccin
use
mva
schikv
mva
schikv
respect
result
demonstr
chikv
chikv
abl
induc
titr
sinc
nt
assay
present
use
sever
vaccin
develop
studi
chikv
abl
afford
compar
assess
titter
vaccin
develop
garciaarriaza
et
al
report
mvachikv
vaccin
express
full
structur
cassett
mean
titter
prime
postimmunis
strategi
et
al
develop
attenu
chikv
vaccin
achiev
use
vaccin
final
chikv
neutralis
titr
assess
human
sera
yield
titr
three
differ
chikv
patient
return
mauritiu
la
reunion
seychel
respect
therefor
mean
titr
achiev
prime
primeboost
regim
reflect
capac
viralvector
vaccin
induc
physiolog
relev
titr
licens
vaccin
yet
avail
prevent
chikv
infect
experiment
vaccin
reach
clinic
trial
three
still
activ
lead
field
lead
vaccin
consist
viruslik
particl
present
antigen
similar
chikv
without
replic
stimul
immun
respons
requir
multipl
inject
induc
antibodi
titr
thu
increas
cost
logist
use
lowincom
countri
anoth
develop
consist
recombin
live
attenu
measl
viru
mv
express
surfac
chikv
antigen
vaccin
immunogen
safe
human
also
requir
dose
regard
adenovir
vector
one
human
adenoviru
express
chikv
structur
antigen
publish
unfortun
human
adenoviralvector
vaccin
suitabl
vaccin
human
due
widespread
presenc
wildtyp
adenoviru
elicit
antiadenoviru
immun
thu
decreas
vaccin
effici
henc
use
chimpanze
adenoviru
circumv
problem
ideal
chikv
vaccin
develop
safeti
immunogen
achiev
singl
vaccin
dose
adjuv
requir
simpl
robust
develop
could
benefit
lowincom
set
afford
simplif
logist
essenti
deliv
vaccin
target
popul
howev
event
booster
vaccin
need
mvabas
vaccin
chikv
could
use
given
suitabl
clinic
set
capabl
produc
million
dose
costeffect
background
immunogen
safeti
profil
human
suitabl
produc
good
manufactur
practic
gmp
schikv
vaccin
relev
candid
explor
preclin
clinic
trial
